Using artificial intelligence to learn optimal regimen plan for Alzheimer’s disease
Abstract
Alzheimer’s disease (AD) is a progressive neurological disorder with no specific curative medications. Sophisticated clinical skills are crucial to optimize treatment regimens given the multiple coexisting comorbidities in the patient population.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 18, 2023
- Source ID
- 10.1093/jamia/ocad135
Entities
People
- Kritib Bhattarai
- Nansu Zong
- Qiying Dai
- Sivaraman Rajaganapathy
- The Alzheimer’s Disease Neuroimaging Initiative*
- The Australian Imaging Biomarkers And Lifestyle Flagship Study Of Ageing
- Trisha Das
- Xiaoqian Jiang
- Xiaoyang Li
- Yejin Kim
- Yongbin Chen
Organizations
- Alzheimer's Association
- Alzheimer's Disease Neuroimaging Initiative
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Eli Lilly and Company
- Istituto Superiore di Sanità
- Luther College
- Mayo Clinic
- National Institute of Biomedical Imaging and Bioengineering
- National Institute of General Medical Sciences
- National Institute on Aging
- National Institutes of Health
- United States Department of Defense
- University of Illinois Urbana–Champaign
- University of Texas System